{
    "nct_id": "NCT05571839",
    "official_title": "A Phase 1 Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors",
    "inclusion_criteria": "* All Parts: Participants must have disease that is relapsed, refractory, or intolerant to standard of care. Participants must have histologically or cytologically confirmed metastatic malignancy.\n* Participants must have one of the following tumor types:\n\n  * Parts A and B: Participants must have metastatic or unresectable cutaneous melanoma.\n  * Part C: Participants must have one of the following tumor types:\n\n    * Cutaneous Melanoma\n    * Non-small Cell Lung Cancer (NSCLC)\n    * Colorectal Cancer (CRC)\n    * Pancreatic Cancer\n    * Mesothelioma\n* A pre-treatment biopsy or submission of archival tissue is required\n* For participants with cutaneous melanoma\n\n  * Must have been previously treated with an anti-programmed death-1 (anti-PD-1) or anti-programmed death ligand-1 (anti-PD-L1) agent given alone or with other therapies.\n  * Participants with a targetable BRAF mutation must have been treated with, been intolerant of, or been deemed ineligible to receive treatment with BRAF/MEK targeted therapy prior to study entry.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Measurable disease per RECIST v1.1 at baseline\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.\n* Active central nervous system metastases or leptomeningeal disease. Participants with previously treated brain metastases may participate provided they are:\n\n  * clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment,\n  * they have no new or enlarging brain metastases,\n  * and are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug.\n* Prior therapies cannot include any drugs targeting CD228 or 4-1BB\n* Immunotherapy, biologics, and/or other approved or investigational antitumor treatment that is not completed 4 weeks prior to first dose of study drug, or within 2 weeks prior to the first dose of study drug if the underlying disease has progressed on treatment\n* Melanoma subtypes including acral, uveal, and mucosal are excluded",
    "miscellaneous_criteria": ""
}